HK Stock MarketDetailed Quotes

02196 FOSUN PHARMA

Watchlist
  • 12.000
  • +0.140+1.18%
Not Open Apr 25 16:09 CST
32.07BMarket Cap12.12P/E (TTM)

FOSUN PHARMA Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
(Q3)Mar 31, 2022
(FY)Dec 31, 2021
(Q9)Sep 30, 2021
Turnover
-5.85%41.25B
-2.92%30.7B
0.16%21.32B
4.68%10.87B
12.73%43.81B
16.91%31.62B
26.10%21.28B
28.91%10.38B
28.85%38.86B
22.38%27.05B
Operating income
-5.85%41.25B
-2.92%30.7B
0.16%21.32B
4.68%10.87B
12.73%43.81B
16.91%31.62B
26.10%21.28B
28.91%10.38B
28.85%38.86B
22.38%27.05B
Cost of sales
6.80%-21.6B
----
7.60%-10.7B
----
-14.53%-23.17B
----
-40.23%-11.58B
----
-47.30%-20.23B
----
Operating expenses
6.80%-21.6B
6.70%-15.78B
7.60%-10.7B
9.67%-5.29B
-14.53%-23.17B
-24.03%-16.91B
-40.23%-11.58B
-50.91%-5.86B
-47.30%-20.23B
-39.79%-13.64B
Gross profit
-4.79%19.65B
1.43%14.92B
9.41%10.62B
23.28%5.58B
10.77%20.64B
9.68%14.71B
12.56%9.7B
8.42%4.52B
13.42%18.63B
8.62%13.41B
Selling expenses
-5.90%-9.71B
-11.23%-7.23B
-21.46%-5.07B
-21.59%-2.52B
-0.77%-9.17B
0.94%-6.5B
0.86%-4.18B
0.51%-2.07B
-11.51%-9.1B
-4.40%-6.56B
Administrative expenses
-14.80%-4.5B
-20.61%-3.17B
-22.11%-2.1B
-25.25%-991.09M
-18.15%-3.92B
-16.73%-2.63B
-14.44%-1.72B
-17.46%-791.31M
-9.16%-3.31B
-12.40%-2.25B
Research and development expenses
-1.02%-4.35B
-10.22%-3.16B
-16.81%-2.13B
-19.66%-968.87M
-12.11%-4.3B
-18.60%-2.86B
-16.98%-1.83B
-26.35%-809.68M
-37.27%-3.84B
-28.55%-2.41B
Profit from asset sales
----
-95.50%6.3M
----
-173.65%-507.68K
----
2,026.44%140.1M
----
-120.77%-185.52K
----
-495.23%-7.27M
Revaluation surplus
----
141.76%806.34M
----
89.13%-147.61M
----
-245.96%-1.93B
----
-2,628.67%-1.36B
----
38,527.73%1.32B
-Changes in the fair value of other assets
----
141.76%806.34M
----
89.13%-147.61M
----
-245.96%-1.93B
----
-2,628.67%-1.36B
----
38,527.73%1.32B
Impairment and provision
-101.82%-131.93M
-189.88%-372.49M
-153.61%-57.98M
-328.87%-25.6M
11.68%-65.37M
51.81%-128.49M
-54.42%-22.86M
21.40%-5.97M
29.40%-74.02M
-280.76%-266.63M
-Other impairment is provision
-101.82%-131.93M
-189.88%-372.49M
-153.61%-57.98M
-328.87%-25.6M
11.68%-65.37M
51.81%-128.49M
-54.42%-22.86M
21.40%-5.97M
29.40%-74.02M
-280.76%-266.63M
Operating interest expense
----
----
-37.47%-603.38M
----
----
----
---438.91M
----
6.63%-822.54M
----
Special items of operating profit
353.64%1.09B
-24.67%2.49B
2,266.92%992.21M
-46.80%828.41M
-91.36%239.26M
62.78%3.3B
-97.11%41.92M
199.90%1.56B
68.10%2.77B
5.90%2.03B
Operating profit
-40.08%2.05B
4.02%4.1B
5.12%1.64B
70.06%1.69B
-19.44%3.43B
-22.64%3.94B
-43.83%1.56B
-22.91%992.85M
37.32%4.25B
31.35%5.09B
Financing income
28.66%363.65M
----
----
----
--282.64M
----
----
----
----
----
Financing cost
-37.46%-1.32B
-99.46%-756.08M
----
-144.12%-261.26M
---963.81M
3.66%-379.07M
----
16.70%-107.02M
----
19.22%-393.46M
Share of profits of associates
15.36%2.39B
----
24.43%1.12B
----
1.60%2.07B
----
-2.92%898.58M
----
18.85%2.04B
----
Share of profit from joint venture company
13.63%-202.03M
----
3.74%-95.84M
----
5.44%-233.93M
----
-6.13%-99.56M
----
-85.65%-247.39M
----
Special items of earning before tax
----
73.78%-49.74M
----
-410.57%-42.38M
----
-474.73%-189.71M
----
41.92%-8.3M
----
-11.11%-33.01M
Earning before tax
-28.46%3.28B
-2.33%3.29B
12.85%2.66B
57.80%1.38B
-24.20%4.58B
-27.76%3.37B
-28.62%2.36B
-23.37%877.53M
29.18%6.04B
38.86%4.67B
Tax
41.06%-369.5M
-4.43%-638.65M
-19.87%-610.25M
-11.16%-270.51M
41.21%-626.92M
16.37%-611.54M
7.55%-509.09M
-46.15%-243.36M
-44.53%-1.07B
-19.81%-731.27M
After-tax profit from continuing operations
-26.46%2.91B
-3.83%2.65B
10.92%2.05B
75.70%1.11B
-20.55%3.95B
-29.87%2.76B
-32.84%1.85B
-35.20%634.16M
26.30%4.98B
43.09%3.93B
Earning after tax
-26.46%2.91B
-3.83%2.65B
10.92%2.05B
75.70%1.11B
-20.55%3.95B
-29.87%2.76B
-32.84%1.85B
-35.20%634.16M
26.30%4.98B
43.09%3.93B
Minority profit
134.84%508.8M
14.66%370.74M
-12.93%267.75M
-28.33%127.28M
-12.48%216.66M
-12.66%323.34M
13.38%307.51M
35.08%177.59M
-10.68%247.56M
36.65%370.21M
Profit attributable to shareholders
-35.81%2.4B
-6.29%2.28B
15.68%1.78B
116.17%986.97M
-20.97%3.74B
-31.66%2.44B
-37.89%1.54B
-46.11%456.57M
29.10%4.73B
43.80%3.56B
Basic earnings per share
-37.06%0.9
-8.51%0.86
11.67%0.67
105.56%0.37
-22.70%1.43
-32.37%0.94
-38.14%0.6
-45.45%0.18
29.37%1.85
43.30%1.39
Diluted earnings per share
-37.06%0.9
-9.57%0.85
11.67%0.67
105.56%0.37
-22.70%1.43
-32.37%0.94
-38.14%0.6
-45.45%0.18
29.37%1.85
43.30%1.39
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
Audit Opinions
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
Auditor
Ernst & Young (Special General Partnership)
--
--
--
Ernst & Young (Special General Partnership)
--
--
--
Ernst & Young (Special General Partnership)
--
(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022(Q3)Mar 31, 2022(FY)Dec 31, 2021(Q9)Sep 30, 2021
Turnover -5.85%41.25B-2.92%30.7B0.16%21.32B4.68%10.87B12.73%43.81B16.91%31.62B26.10%21.28B28.91%10.38B28.85%38.86B22.38%27.05B
Operating income -5.85%41.25B-2.92%30.7B0.16%21.32B4.68%10.87B12.73%43.81B16.91%31.62B26.10%21.28B28.91%10.38B28.85%38.86B22.38%27.05B
Cost of sales 6.80%-21.6B----7.60%-10.7B-----14.53%-23.17B-----40.23%-11.58B-----47.30%-20.23B----
Operating expenses 6.80%-21.6B6.70%-15.78B7.60%-10.7B9.67%-5.29B-14.53%-23.17B-24.03%-16.91B-40.23%-11.58B-50.91%-5.86B-47.30%-20.23B-39.79%-13.64B
Gross profit -4.79%19.65B1.43%14.92B9.41%10.62B23.28%5.58B10.77%20.64B9.68%14.71B12.56%9.7B8.42%4.52B13.42%18.63B8.62%13.41B
Selling expenses -5.90%-9.71B-11.23%-7.23B-21.46%-5.07B-21.59%-2.52B-0.77%-9.17B0.94%-6.5B0.86%-4.18B0.51%-2.07B-11.51%-9.1B-4.40%-6.56B
Administrative expenses -14.80%-4.5B-20.61%-3.17B-22.11%-2.1B-25.25%-991.09M-18.15%-3.92B-16.73%-2.63B-14.44%-1.72B-17.46%-791.31M-9.16%-3.31B-12.40%-2.25B
Research and development expenses -1.02%-4.35B-10.22%-3.16B-16.81%-2.13B-19.66%-968.87M-12.11%-4.3B-18.60%-2.86B-16.98%-1.83B-26.35%-809.68M-37.27%-3.84B-28.55%-2.41B
Profit from asset sales -----95.50%6.3M-----173.65%-507.68K----2,026.44%140.1M-----120.77%-185.52K-----495.23%-7.27M
Revaluation surplus ----141.76%806.34M----89.13%-147.61M-----245.96%-1.93B-----2,628.67%-1.36B----38,527.73%1.32B
-Changes in the fair value of other assets ----141.76%806.34M----89.13%-147.61M-----245.96%-1.93B-----2,628.67%-1.36B----38,527.73%1.32B
Impairment and provision -101.82%-131.93M-189.88%-372.49M-153.61%-57.98M-328.87%-25.6M11.68%-65.37M51.81%-128.49M-54.42%-22.86M21.40%-5.97M29.40%-74.02M-280.76%-266.63M
-Other impairment is provision -101.82%-131.93M-189.88%-372.49M-153.61%-57.98M-328.87%-25.6M11.68%-65.37M51.81%-128.49M-54.42%-22.86M21.40%-5.97M29.40%-74.02M-280.76%-266.63M
Operating interest expense ---------37.47%-603.38M---------------438.91M----6.63%-822.54M----
Special items of operating profit 353.64%1.09B-24.67%2.49B2,266.92%992.21M-46.80%828.41M-91.36%239.26M62.78%3.3B-97.11%41.92M199.90%1.56B68.10%2.77B5.90%2.03B
Operating profit -40.08%2.05B4.02%4.1B5.12%1.64B70.06%1.69B-19.44%3.43B-22.64%3.94B-43.83%1.56B-22.91%992.85M37.32%4.25B31.35%5.09B
Financing income 28.66%363.65M--------------282.64M--------------------
Financing cost -37.46%-1.32B-99.46%-756.08M-----144.12%-261.26M---963.81M3.66%-379.07M----16.70%-107.02M----19.22%-393.46M
Share of profits of associates 15.36%2.39B----24.43%1.12B----1.60%2.07B-----2.92%898.58M----18.85%2.04B----
Share of profit from joint venture company 13.63%-202.03M----3.74%-95.84M----5.44%-233.93M-----6.13%-99.56M-----85.65%-247.39M----
Special items of earning before tax ----73.78%-49.74M-----410.57%-42.38M-----474.73%-189.71M----41.92%-8.3M-----11.11%-33.01M
Earning before tax -28.46%3.28B-2.33%3.29B12.85%2.66B57.80%1.38B-24.20%4.58B-27.76%3.37B-28.62%2.36B-23.37%877.53M29.18%6.04B38.86%4.67B
Tax 41.06%-369.5M-4.43%-638.65M-19.87%-610.25M-11.16%-270.51M41.21%-626.92M16.37%-611.54M7.55%-509.09M-46.15%-243.36M-44.53%-1.07B-19.81%-731.27M
After-tax profit from continuing operations -26.46%2.91B-3.83%2.65B10.92%2.05B75.70%1.11B-20.55%3.95B-29.87%2.76B-32.84%1.85B-35.20%634.16M26.30%4.98B43.09%3.93B
Earning after tax -26.46%2.91B-3.83%2.65B10.92%2.05B75.70%1.11B-20.55%3.95B-29.87%2.76B-32.84%1.85B-35.20%634.16M26.30%4.98B43.09%3.93B
Minority profit 134.84%508.8M14.66%370.74M-12.93%267.75M-28.33%127.28M-12.48%216.66M-12.66%323.34M13.38%307.51M35.08%177.59M-10.68%247.56M36.65%370.21M
Profit attributable to shareholders -35.81%2.4B-6.29%2.28B15.68%1.78B116.17%986.97M-20.97%3.74B-31.66%2.44B-37.89%1.54B-46.11%456.57M29.10%4.73B43.80%3.56B
Basic earnings per share -37.06%0.9-8.51%0.8611.67%0.67105.56%0.37-22.70%1.43-32.37%0.94-38.14%0.6-45.45%0.1829.37%1.8543.30%1.39
Diluted earnings per share -37.06%0.9-9.57%0.8511.67%0.67105.56%0.37-22.70%1.43-32.37%0.94-38.14%0.6-45.45%0.1829.37%1.8543.30%1.39
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)
Audit Opinions Unqualified Opinion------Unqualified Opinion------Unqualified Opinion--
Auditor Ernst & Young (Special General Partnership)------Ernst & Young (Special General Partnership)------Ernst & Young (Special General Partnership)--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg